The global Women’s Health Market is expected to reach USD
51.3 billion by 2025, according to a new report by Grand View Research, Inc.
Increasing female geriatric population, introduction of various drugs related
to women’s health, and favorable government policies are some of the factors
expected to drive growth during the forecast period.
Women are more prone to certain
diseases, such as osteoporosis, osteoarthritis, anemia, menstruation-related
disorders, depression, and obesity. Hence, increase in incidence of these
conditions is likely to boost the market in the coming years. According to
International Osteoporosis Foundation, global prevalence of osteoporosis among
women was over 200.0 million in 1990, and this is anticipated to reach 680.0
million in 2050.
Government and various private
organizations are working toward improving women’s health across the world, and
this is likely to drive growth in the coming years.
Reimbursement coverage
provided to women is also a key factor driving the market in developed
countries. For instance, various coverage plans in the U.S. provide preventive
services for women without charging any copayment. These include screening for
anemia, hepatitis B, & breast cancer on a routine basis, folic acid
supplements for women who are likely to be pregnant, and contraceptive methods,
among others.
Further Key Findings from the Report Suggest:
- Presence of a large female geriatric
population, which is susceptible to chronic diseases, is expected to boost
growth
- In 2016, postmenopausal osteoporosis accounted
for the largest share of the market due to high incidence of osteoporosis
in women after menopause, presence of several major players, and
cost-effectiveness of this treatment
- Contraceptive segment is likely to witness
fastest growth during the forecast period due to increase in awareness and
usage, government initiatives, technological developments, and favorable
regulatory scenario. For instance, in June 2017, Agile Therapeutics, Inc.
resubmitted an NDA for Twirla, an investigational low-dose combined
hormonal contraceptive patch
- Geographically, North America held the largest
share of more than 30% in 2016 due to presence of major market players,
high awareness about regular health check-ups for women, coverage for
screening, and increased healthcare expenditure
- Asia Pacific is expected to exhibit fastest
growth during the forecast period due to increasing investments by players
in the region, rising awareness about women’s health, and initiatives by
various governments and private organizations to improve awareness and
access to women’s health products
- Some of the key players operating in the
women’s health market are Allergan; Bayer AG; Merck & Co., Inc.;
Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Agile Therapeutics;
Amgen, Inc.; AstraZeneca; Bristol-Myers Squibb Company; and Ferring B.V.
No comments:
Post a Comment